Business history is also littered with companies and industries destroyed by new technologies.

Monoclonal antibodies have and continue to upend the pharmaceutical industry.

Very few of us doubt that Cytodyn needs to partner to reach scale post-approval.

IMO, it will not be quick or easy for others to develop a better CCR5 receptor antibody until leronlimab patent expiration.

This be provide quite a moat for Cytodyn. Time will tell.

Invest according to your beliefs. I have.